This is most interesting to me. Now we are getting into real...

This is most interesting to me. Now we are getting into real nitty gritty details. Seems the initial waiver will be for 12+ aged patients. I feel the over prescribe of unnecessary antibiotics would be very high in under 12s, as well. So one will assume if the first 12+ waiver gets up (with $2.9 mill from BARDA coming in to cover the study), the study will roll into the next under 12 group.



FYI this shows how wrong I was to poo poo the waiver study. The fact they did the cap raise to prove they will do it, likely was a big catalyst for the BARDA money. Now with the $3.5 mill they raised for study, the cap raise, they dont need to spend it, so they can do a buy back (too soon? )